• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.

作者信息

Kuraoka Naosuke, Hara Kazuo, Terai Shuji, Yatabe Yasushi, Horio Yoshitsugu

机构信息

Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan.

Department of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.

出版信息

Endoscopy. 2018 Sep;50(9):E259-E261. doi: 10.1055/a-0640-2392. Epub 2018 Jul 3.

DOI:10.1055/a-0640-2392
PMID:29969801
Abstract
摘要

相似文献

1
Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer.非小细胞肺癌患者中纳武利尤单抗相关（诱导性）溃疡性胆管炎的经口胆管镜检查
Endoscopy. 2018 Sep;50(9):E259-E261. doi: 10.1055/a-0640-2392. Epub 2018 Jul 3.
2
Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports.程序性细胞死亡蛋白1抑制剂相关硬化性胆管炎的经口胆管镜检查：三例病例报告
Endoscopy. 2019 Dec;51(12):E402-E403. doi: 10.1055/a-0948-1271. Epub 2019 Jul 24.
3
Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.三例与用于治疗非小细胞肺癌的抗程序性细胞死亡和程序性细胞死亡配体药物相关的免疫性胆管炎。
Eur J Cancer. 2019 Jul;115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24.
4
Endoscopic ultrasound-guided gallbladder drainage to facilitate biliary rendezvous for the management of cholangitis due to choledocholithiasis.内镜超声引导下胆囊引流以促进胆管会师，用于治疗胆总管结石所致胆管炎。
Endoscopy. 2017 Dec;49(12):E309-E310. doi: 10.1055/s-0043-119351. Epub 2017 Oct 9.
5
Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.肝胆胰：与纳武利尤单抗相关的胆管病。
J Gastroenterol Hepatol. 2018 Oct;33(10):1695. doi: 10.1111/jgh.14136. Epub 2018 Apr 29.
6
[Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.].[转移性肺腺癌。纳武单抗作为二线治疗：在未解决的问题和充满希望的未来之间。病例报告。]
Recenti Prog Med. 2018 Mar;109(3):197e-201e. doi: 10.1701/2876.29005.
7
Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.一名复发性肺腺癌患者出现与纳武利尤单抗相关的严重血小板减少症：病例报告及文献复习
J Med Case Rep. 2019 Oct 24;13(1):316. doi: 10.1186/s13256-019-2245-y.
8
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.纳武利尤单抗诱发的吉兰-巴雷综合征合并在一名经过大量预处理的肺腺癌患者中出现显著疾病反应
Clin Lung Cancer. 2020 Mar;21(2):e65-e73. doi: 10.1016/j.cllc.2019.11.001. Epub 2019 Nov 21.
9
Inflammatory Bowel Disease in an Elderly Woman After Nivolumab Administration.纳武单抗治疗后一名老年女性患炎症性肠病
Am J Gastroenterol. 2017 Nov;112(11):1636. doi: 10.1038/ajg.2017.372.
10
Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.对吉非替尼耐药后停用纳武单抗后的持久反应。
Clin Respir J. 2019 Oct;13(10):657-658. doi: 10.1111/crj.13065. Epub 2019 Aug 23.

引用本文的文献

1
Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges.免疫检查点抑制剂介导的肝损伤：一个充满新挑战的前沿领域。
Liver Int. 2025 Feb;45(2):e16198. doi: 10.1111/liv.16198.
2
Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma.一名IV期肺腺癌患者并发纳武单抗诱导的胃炎和胆管炎并伴有胆道出血
Cureus. 2023 Oct 2;15(10):e46392. doi: 10.7759/cureus.46392. eCollection 2023 Oct.
3
Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis.
在免疫检查点抑制剂诱导的胆管炎接受类固醇治疗后经口胆管镜检查中观察到的袋状褶皱的临床反应。
Endoscopy. 2022 Dec;54(S 02):E1020-E1021. doi: 10.1055/a-1899-8619. Epub 2022 Aug 24.
4
Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.免疫检查点抑制剂相关胰腺炎和胆管炎的临床特征，包括影像学和内镜检查结果
Healthcare (Basel). 2022 Apr 20;10(5):763. doi: 10.3390/healthcare10050763.
5
Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.免疫检查点抑制剂所致免疫相关性胆管炎：临床特征与管理的系统评价。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e858-e867. doi: 10.1097/MEG.0000000000002280.
6
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.肝毒性是限制免疫检查点抑制剂使用增加的一个因素。
JHEP Rep. 2020 Aug 11;2(6):100170. doi: 10.1016/j.jhepr.2020.100170. eCollection 2020 Dec.
7
Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient.帕博利珠单抗诱发的非小细胞肺癌患者继发性硬化性胆管炎
Respirol Case Rep. 2020 Apr 10;8(5):e00560. doi: 10.1002/rcr2.560. eCollection 2020 Jul.
8
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.程序性细胞死亡蛋白-1 抑制剂相关硬化性胆管炎：系统评价。
World J Gastroenterol. 2020 Jan 21;26(3):353-365. doi: 10.3748/wjg.v26.i3.353.
9
Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.纳武利尤单抗诱发非小细胞肺癌患者胆管炎：病例系列及文献综述
Mol Clin Oncol. 2019 Nov;11(5):439-446. doi: 10.3892/mco.2019.1923. Epub 2019 Sep 18.
10
Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature.泼尼松龙成功治疗纳武单抗相关胆管炎：一例报告及文献复习
Intern Med. 2019 Jun 15;58(12):1747-1752. doi: 10.2169/internalmedicine.2330-18. Epub 2019 Feb 25.